[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632511":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":19,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":19,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":19,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"experimental group","Postoperatively, administer Anrikefon injection intravenously at a dose of 1 μg\u002Fkg every 8 hours for three consecutive days.",[12,13],"Drug: Experimental Group","Drug: Anrikefon",[15,20],{"type":16,"name":17,"description":10,"armGroupLabels":18,"otherNames":19},"DRUG","Experimental Group",[9],null,{"type":16,"name":21,"description":22,"armGroupLabels":23,"otherNames":19},"Anrikefon","Postoperatively, intravenous injection of Anrikefon injection was administered at a dose of 1 μg\u002Fkg, every 8 hours, for three consecutive days as an intervention",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"yudong QIU","CONTACT","0086+13809021967","yudongqiu510@163.com",[31],{"facility":32,"status":33,"city":34,"state":19,"zip":19,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"NanJing drum tower hospital","RECRUITING","Nanjing","China","CN",{"type":38,"coordinates":39},"Point",[40,41],118.77778,32.06167,{"lat":41,"lon":40},[44,45],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},{"name":19,"role":27,"phone":19,"phoneExt":19,"email":46},"1808456151@qq.com",{"type":48,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100632511","phase-2-safety-and-efficacy-of-anricfen-for-postoperative-analgesia-and-rehabilitation-promotion-after-pancreaticoduodenectomyintervention-measures-for-normal-adults-administer-ariceptin-injection-intravenously-post-operation-at-a-dose-of-1-gkgevery-8-hours-for-three-consecutive-days-after-surgery-100632511",false,"NCT07514637","Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg\u002FKgevery 8 Hours for Three Consecutive Days After Surgery.","The Safety and Efficacy of Aniracetamfen for Postoperative Analgesia and Rehabilitation After Pancreaticoduodenectomy: A Single-center, Single-arm Clinical Study","Inclusion Criteria:\n\n* Patients who underwent pancreatic surgery, including pancreaticoduodenectomy (PD), pancreatic-preserving pancreaticoduodenectomy (PPPD), and laparoscopic pancreaticoduodenectomy (LPD)\n* Age ≥ 18 years old and \\\u003C 80 years old\n* ASA Ⅰ-Ⅲ\n* Be able to clearly understand and voluntarily participate in the research\n\nExclusion Criteria:\n\n* Merging severe primary diseases involving the heart, brain, liver, kidneys and hematopoietic system\n* History of long-term use of psychotropic drugs and cognitive dysfunction\n* Having a history of acute poisoning from alcohol, sleeping pills, painkillers or other drugs that affect the central nervous system\n* Pregnancy or lactation period\n* History of allergy to NSAIDs, opioids, or to the test medication\n* Drug users, alcoholics, and opiate abusers\n* Those who had a history of chronic pain before the operation and a history of long-term use of analgesics and\u002For sedatives\n* Those who had thyroid dysfunction before the operation","ALL","18 Years","80 Years",{"count":60,"type":61},35,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients.\n\nMain objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy.\n\nSecondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy.\n\nExploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.",[67],"Patients Who Undergo Pancreaticoduodenectomy",[69,70,71,72],"pancreaticoduodenectomy","Peripheral κ receptor agonist","analgesia","Promote recovery","2026-04-01",{"date":75,"type":76},"2026-04-07","ACTUAL",{"date":78,"type":76},"2025-11-25",{"date":80,"type":61},"2026-03-31",{"name":5,"class":6},1]